DEFA14A ·Filed Apr 16, 2026

EBS

Emergent BioSolutions Inc.
NEUTRAL
Impact 3/10
Horizonimmediate Processed5mo ago SEC0001193125-26-158134
Proxy solicitation materials
Actionable Insight • Neutral

Investors should review proxy materials for details on board nominees, executive pay, and any shareholder proposals ahead of the vote. No material changes or surprises are indicated in this filing.

DirectionNeutral
Confidencehigh
Horizonimmediate
Final — all horizons settled through T+60d ⚠ clustered
EBS ▼ -7.08% at T+60d
NEUTRAL call ✗ call lost -7.08% · α vs SPY -14.12% · entry $8.62 → $8.01
Entry anchored
Apr 15, 03:59 PM ET
via exchange tick
T+1d
+2.20%
call +2.20% · α +0.99%
$8.81
settled 6mo ago
T+5d
-6.15%
call -6.15% · α -7.13%
$8.09
settled 5mo ago
T+20d
-3.36%
call -3.36% · α -9.18%
$8.33
settled 5mo ago
T+60d
-7.08%
call -7.08% · α -14.12%
$8.01
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

Emergent BioSolutions Inc. filed its definitive proxy statement for the 2026 annual shareholder meeting, scheduled for April 29, 2026. The filing serves as a reminder for shareholders to vote on matters including director elections and executive compensation, with voting accessible via proxy.

Key Facts

  • Filing is a Definitive Proxy Statement (DEFA14A) for the 2026 annual meeting.
  • Annual meeting date is April 29, 2026, at 9:00 AM Eastern Time.
  • Shareholders of record as of March 6, 2026, are eligible to vote.
  • Voting can be completed by proxy, with instructions sent via email through E*TRADE.

Financial Impact

No direct financial impact; routine corporate governance filing.

governanceshareholder engagement

Risk Factors

  • Low engagement from shareholders could affect voting outcomes on key proposals.
  • Potential for activist shareholder activity if dissatisfaction with management arises.

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001193125-26-158134
Document: 0001193125-26-158134-index-headers.html0001193125-26-158134
Document: 0001193125-26-158134-index.html0001193125-26-158134
Document: 0001193125-26-158134.txt0001193125-26-158134
16 reports for EBS
Performance horizon
60% Hit rate 3 of 5 directional calls best @ T+20▲ +14.89%Apr 29, 2026
Filters
Rows
Reports for EBS — sortable, filterable
TypeNow
Aug 10, 2026
7w ago
Press Release
BEARISH ★ 7/10
$4.45 $5.68▼ −27.64%▼ −28.70%$6.29 (−41.35%)
Jun 29, 2026
13w ago
8-K
BULLISH ★ 5/10
$8.46 $7.26▼ −14.18%▼ −13.90%$6.29 (−25.65%)
Jun 4, 2026
17w ago
Press Release
NEUTRAL ★ 2/10
$8.44 $8.28▼ −1.90%▼ −0.52%$6.29 (−25.47%)
Apr 30, 2026
22w ago
Press Release
MIXED ★ 6/10
$8.47 $8.49▲ +0.24%▼ −5.05%$6.29 (−25.74%)
Apr 30, 2026
22w ago
Insider Cluster
NEUTRAL ★ 2/10
$8.23 $9.18▲ +11.54%▲ +6.58%$6.29 (−23.57%)
Apr 29, 2026
22w ago
Press Release
BULLISH ★ 4/10
$7.99 $9.18▲ +14.89%▲ +8.85%$6.29 (−21.28%)
Apr 29, 2026
22w ago
Press Release
NEUTRAL ★ 1/10
$7.99 $9.18▲ +14.89%▲ +8.85%$6.29 (−21.28%)
Apr 28, 2026
22w ago
DEFA14A
NEUTRAL ★ 2/10
$8.23 $9.13▲ +10.94%▲ +5.47%$6.29 (−23.57%)
Apr 28, 2026
22w ago
Press Release
NEUTRAL ★ 4/10
$8.23 $9.13▲ +10.94%▲ +5.47%$6.29 (−23.57%)
Apr 27, 2026
22w ago
DEFA14A
NEUTRAL ★ 2/10
$8.23 $9.13▲ +10.94%▲ +5.47%$6.29 (−23.57%)
Showing 10 of 16

US Market Status

Market Open — Closes in 2h 17m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access